Celltrion’s biosimilar ‘Truxima’ acquires approval in Australia
Celltrion announced the company acquired approval of Truxima(generic name: rituximab), an antibody biosimilar for the treatment of hematologic malignancy, from the Australian Therapeutic Goods Administration on the 20th.
‘Truxima’ developed by Celltrion is an antibody biosimilar for the treatmen...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
